Rationale The amygdala and insular cortex are integral to the processing of emotionally salient stimuli. We have shown in healthy volunteers that an anxiolytic agent, lorazepam, dose-dependently attenuates activation of limbic structures. Objective The current study investigated whether administration of a selective serotonin reuptake inhibitor (SSRI), escitalopram, alters the activation of limbic structures. We hypothesized that subchronic (21 days) SSRI treatment attenuates the activation of the amygdala and insula during processing of emotional faces. Materials and methods Thirteen healthy volunteers participated in a double-blind, placebo-controlled, crossover, randomized study. After 21 days of treatment with either escitalopram or placebo, participants underwent functional magnetic resonance imaging (fMRI) during which all subjects completed an emotion face assessment task, which has been shown to elicit amygdala and insula activation. Results Subjects activated the bilateral insula and amygdala after treatment with both escitalopram and placebo. In subjects who were adherent to the protocol (as evidenced by sufficiently high urine concentrations of escitalopram), a reduction in amygdala activation was seen in the escitalopram condition compared to placebo. Conclusion The current investigation provides further evidence for the mechanism of action of SSRIs through the attenuation of activation in brain regions responsible for emotion processing and provides support for the use of blood oxygenation level-dependent fMRI with pharmacological probes to help identify the specific therapeutic effect of these agents in patients with anxiety and mood disorders.
Introduction
The combination of functional magnetic resonance imaging (fMRI) and pharmacological treatment (pharmaco-fMRI) is a novel discipline with the potential to provide a better understanding of the interface between neural systems and drug therapy . In previous studies, we were able to show that the acute administration of an anxiolytic (lorazepam) attenuates limbic and paralimbic structures (amygdala and insula) during emotional face processing (Paulus et al. 2005 ) and risk taking (Arce et al. 2006) . Thus, pharmaco-fMRI may be useful to provide a brain signature of anxiolytics that could help in the development of novel drugs . Serotonin is involved in emotion-related processes Rogers et al. 2003) , and selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed antidepressants (Masand and Gupta 1999; Nutt et al. 1999 ) initially developed to regulate brain serotonin levels to treat affective disorders (Mendlewicz 1999) . Moreover, these drugs are also an important aspect of the chronic treatment of individuals with anxiety disorders. Thus, understanding how prolonged (i.e., beyond acute) administration of an SSRI affects limbic and paralimbic structures in the brain provides an important next step in determining the usefulness of pharmaco-fMRI for the development of new drugs.
One of the actions of SSRIs is to block the reuptake of secreted serotonin, preventing it from being transported back into the presynaptic neuron. It is also believed that the antidepressant (and, possibly, the anxiolytic) actions of SSRIs involve effects that extend beyond serotonin reuptake (Carrasco and Sandner 2005; Vaswani et al. 2003; Waugh and Goa 2003) . Nevertheless, it is still unknown how they work to normalize abnormal cognitive and emotional processes. The effects of SSRIs in affective disorders are likely to be the result of the interaction between serotonin (5-HT) pathways with the cortical and subcortical circuitry thought to be involved in the processing of emotional stimuli (Fu et al. 2004) . Their acute/early stage vs chronic treatment effects are sometimes opposite in that an early exacerbation of anxiety symptoms is often followed by an anxiolytic effect if treatment is not interrupted (Harmer et al. 2006; Kent et al. 1998 ). Acute oral (Browning et al. 2007 ) and intravenous administration of the SSRI citalopram increases the processing of anxiety-related stimuli in healthy volunteers, whereas repeated administration impairs the recognition of fearful stimuli (Harmer et al. 2004 ) and attenuates amygdala activation (Harmer et al. 2006) .
Serotonin receptors are widely expressed within the amygdala (Kent et al. 1998) , considered part of the circuitry involved in the detection of emotionally relevant stimuli, which, in turn, is a process targeted by SSRIs (Harmer et al. 2006) . The amygdala, as revealed by functional neuroimaging studies, is involved in fear conditioning , reward-related processing (Breiter and Rosen 1999) , encoding of emotionally salient stimuli (Canli et al. 2000) , risk taking (Ernst et al. 2002) , processing positively valenced stimuli (Garavan et al. 2001) , and appetitive or aversive olfactory learning (Gottfried et al. 2002) , as well as in the pathophysiology of anxiety disorders (Charney 2003; Rauch et al. 2003) . The insula, along with the anterior cingulate gyrus and medial prefrontal cortex, plays a crucial role in the detection of emotionally salient stimuli Phillips et al. 1998) , generation of an affective response, and regulation of that affective state (Phillips et al. 2003) . This cortical region has afferent and efferent connections to the medial and orbitofrontal cortex (Ongur and Price 2000) , anterior cingulate gyrus, and several amygdalar nuclei as well as the nucleus accumbens (Reynolds and Zahm 2005) . Functionally, it has been typically associated with feelings of disgust (Phillips et al. 1998) , although more recent studies have suggested its importance in the anticipation of emotional stimuli (Simmons et al. 2004) , aversive conditioning (Paulus et al. 2003) , and physiological processing (Critchley et al. 2004 ). Thus, this area appears to be a confluent point of emotion, cognition, and physiology. Given the importance of the insula and amygdala in emotional processing, the functional status of these structures has been proposed to serve as a biomarker to index the effect of anxiolytic and/or antidepressant treatments (Paulus et al. 2005 ).
For the current investigation, we studied the properties of a widely prescribed SSRI, escitalopram. Although several studies have used pharmaco-fMRI to assess the neural correlates of certain antidepressant agents (e.g., Chen et al. 2007; Del-Ben et al. 2005; Fu et al. 2007; Harmer et al. 2006; Rose et al. 2006; Sheline et al. 2001; Vollm et al. 2006) , to our knowledge, this is the first study to implement a sub-chronic, placebo-control crossover design using a group of healthy volunteers. The goal of this study was to examine whether treatment with escitalopram affects emotional processing in healthy volunteers as measured by activation in the insula and amygdala. Considering the pivotal role of the insula in subjective feeling states and interoceptive awareness (Craig 2002; Critchley et al. 2004) as well as its presumed role in anxiety disorders (Critchley et al. 2004; Paulus and Stein 2006) and the efficacy of SSRIs to treat such, we hypothesized that escitalopram would attenuate not only amygdala but also insular cortex activation.
This investigation was aimed to determine whether subchronic (21 day) administration of an SSRI, escitalopram, would attenuate the blood oxygenation level-dependent functional magnetic resonance imaging (BOLD-fMRI) activation of limbic and paralimbic structures during emotion processing. A modified emotion face assessment task was used to determine whether this attenuation would occur with emotional faces (angry, fearful, and happy) when compared to a sensorimotor control task. Support for this hypothesis would provide a neurophysiological link between the clinical efficacy of escitalopram as an antianxiety agent and the biological basis of its modulation of limbic and paralimbic structures as key targets for anxiety circuitry.
Materials and methods

Subjects
The University of California, San Diego School of Medicine institutional review board approved the study procedures. All participants provided written informed consent and were paid for their participation. Sixteen healthy, nonsmoking women completed the study (see Fig. 1 ). Two participants were excluded from the analysis due to excessive movement during the fMRI session (more than three instances, at least 4 mm every time), and one subject was excluded because her urine escitalopram was undetectable during the period of time when she was to have been taking escitalopram, indicating nonadherence to the protocol. The remaining 13 subjects were female of ages 19 to 27 years (mean±SD, 22.4±2.5 years) with 13 to 17 years of education (mean±SD, 15 
Study design
This study was performed in a randomized, crossover, and double blind manner (see Fig. 2 ). Once it was determined that a subject was eligible for the study and informed consent was obtained, the subject was randomized to receive either escitalopram (5 mg/day for the first 3 days, then 10 mg/day for another 18 days) or placebo, administered in identical, capsular form. Subjects were instructed to take the medication each morning throughout each 21-day arm of the study. In between arms, there was a 14-to 28-day washout period, during which the medication was reduced from 10 to 5 mg/day for 3 days, and then discontinued. The study physician (MPP) also met with the subject weekly to address any concerns and to ensure that compliance with the medication was maintained. After completion of each medication arm, subjects were scheduled for an fMRI visit. During this visit and before the scanning session, subjects completed several self-report questionnaires to evaluate their psychological state at that time and provided a urine sample for escitalopram measurement to assess treatment compliance. The results of the urine assay for escitalopram were not made available to the study personnel until after all subjects had completed participation. The urine samples were processed by a contract laboratory, which used gas chromatography for quantitative detection of the parent drug (test sensitivity within the range of 5 and 2,000 Ng/ml).
Task
During fMRI, subjects were tested using a slightly modified version of the emotion face assessment task, along with a general sensorimotor task (for details on the task see Paulus et al. 2005) . Each 5-s trial consisted of a target face (on the top of the computer screen) and two probe faces (on the bottom of the computer screen). Subjects were instructed to match the emotion (angry, fearful, and happy) of the target and probe faces. The trials were block designed, such that each block consisted of 6 consecutive trials in which the target face was either angry, fearful, or happy. During the sensorimotor task, subjects were presented with an analogous configuration of ovals and circles and were instructed to match the shapes of the target and the probe. Each block of the faces and sensorimotor task was presented three times in a pseudorandom order, and a fixation cross was interspersed between each block. Response accuracy and time data were obtained for each trial.
Image acquisition
The BOLD-fMRI data were collected during the task using a Signa EXCITE 3.0 Tesla-GE scanner (T2*-weighted echo planar imaging, TR=2,000 ms, TE=32 ms, FOV=230× 230 mm 3 , 64×64 matrix, 30 2.6-mm axial slices with a 1.4-mm gap, 256 scans). For anatomical reference, a high resolution T1-weighted image (SPGR, TI=450, TR=8 ms, TE=4 ms, FOV=250×250 mm 3 ,flip angle = 12°, 172 sagittally acquired slices,~1 mm 3 voxels) was obtained during the same session. For preprocessing, voxel time series were interpolated to correct for non-simultaneous slice acquisition within each volume. These interpolated values were then corrected for three-dimensional motion.
fMRI analysis pathway/image processing All structural and functional image processing was done with the Analysis of Functional Neuroimages software package (AFNI). The echoplanar images were realigned to a base using a Fourier transform-using the AFNI program 3dvolreg-and then time-corrected for slice acquisition order. Preprocessed time series data for each individual were analyzed using a multiple regression model. For this model, the four orthogonal regressors of interest were (1) happy, (2) angry, (3) fearful, and (4) circle/oval sensorimotor condition. These regressors were convolved with a modified gamma variate function to account for the delay and the dispersion of the hemodynamic response of the BOLD-fMRI signal. Additionally, five nuisance regressors were used to account for residual motion (roll, pitch, and yaw) and to eliminate slow signal drifts (baseline and linear trend). These nine regressors were applied to the AFNI program 3dDeconvolve to calculate the estimated voxelwise response amplitude. To account for individual variation of anatomical landmarks, a Gaussian filter with 6-mm full width at half maximum was applied to the voxel-wise percent signal change data. Data for each subject were normalized to Talairach coordinates. A priori regions of interest-including the amygdala, cingulate cortex, and insula-were used as masks. Based on these three areas, a voxel-wise a priori probability of 0.05 was determined via simulations, which resulted in a corrected cluster-wise activation probability of 0.05 using a minimum volume of 128 µl and two connected voxels (for an amygdala cluster), or 256 µl and four connected voxels (for a cingulate or insular cortex cluster). Using the thresholds and cluster sizes defined above, the corrected voxel-wise probabilities are as follows: amygdala, p<0.012; cingulate cortex, p<0.00610129; and insular cortex, p<0.00006859. The areas of interest were superimposed on each individual's voxel-wise percent signal change brain image. Stereotatic coordinates of the ROIs were based on standardized atlas locations (Talairach and Tournoux 1998) and appropriate clustering sizes were determined using the AFNI function AlphaSim. Only the activations within the areas of interest that survived the volume and voxel connection criteria were extracted and used for further analysis. A task effect was calculated by performing a one sample t test on the placebo condition for the contrast of interest (i.e., all face types vs all shape types). Subjects with detectable escitalopram urine levels were included in a linear regression function using the AFNI program RegAna to assess for the relationship between escitalopram concentrations and BOLD activation.
Statistical analysis
All analyses were carried out with Statistical Package for the Social Sciences 12.0 (Norusis 1990). A mixed model analysis of variance (ANOVA) with subjects as a random variable and treatment condition (placebo or escitalopram) as a within-subjects variable was used to analyze the behavioral measures and neural activation patterns. Behavioral measures are reported as an interaction between treatment type and task condition. Self-report measures are reported as direct comparisons between the placebo and escitalopram conditions. Correlational analyses were conducted for the escitalopram condition by examining the relationship between activation in the bilateral insula, amygdala, and anterior cingulate cortex during the viewing of emotional faces vs. the sensorimotor condition and escitalopram urine concentration as well as behavioral and self-report measures.
Results
Behavioral results
Behavioral results showed that subjects performed the task with nearly perfect accuracy (mean±SD, 97.2±0.7%), which was not affected by escitalopram administration [F (1,12) 
Neuroimaging results
Task effect
As observed in a previous investigation using the same task (Paulus et al. 2005) , subjects demonstrated bilateral amygdala, anterior and posterior insula, visual cortex, and subgenual cingulate activation irrespective of emotion type or drug condition when compared to the sensorimotor control task. Task-related deactivation was detected in the ventral anterior cingulate (see Table 1 ).
Drug condition effect
There were no significant differences in BOLD activity between the placebo and escitalopram conditions during emotional face processing for each of the emotions considered separately (data not shown) nor when collapsing across emotions. The average of all three emotions vs shapes is reflected on Fig. 3 . Within-group two-tailed paired-sample t tests revealed no significant differences for any region of interest. Therefore, we extracted the percent signal change for the anatomically defined regions of interest, which lead to no significant differences between conditions: bilateral amygdala [left, t(12) Fig. 3 ).
Correlations between behavioral measures and functional neuroimaging results
There were no significant correlations between response latency or accuracy, or any self-report measures (i.e., BDI, BSI, SIAS, and STAIS) and the degree of activation in the insula or amygdala during the emotion face assessment task (data not shown).
Correlations between escitalopram urine concentration and functional neuroimaging results
Three subjects who had detectable urine escitalopram levels, nonetheless, had concentrations lower than 500 ng/ml, which was far below the level of all other subjects. Regression analysis was performed to assess the relationship between escitalopram concentration in urine and BOLD activation during emotional processing. All subjects were included in a linear regression function using the AFNI program RegAna. Spearman-rank non-parametric correlations were run to correlate the extracted percent signal change and urine (Lancaster et al. 2000) . b Degrees of freedom (25) concentration levels. Results (see Fig. 4 
Urine concentrations >500 ng/ml
Following the relationship between urine concentration and limbic and paralimbic attenuation, we completed a series of post-hoc analyses in the ten subjects who had urine levels of escitalopram that were well above the lower detection limit. Thus, in this analysis, we only included individuals with urine concentrations above 500 ng/ml (n=10). An ANOVA of face-type × treatment condition did not reveal a significant interaction. To further investigate a possible effect of treatment, we performed between-condition t tests for each of the emotion contrasts. No clusters survived thresholding for the happy-oval contrast. Angry-oval revealed four clusters of greater activation, two in the right [39,−18,19, vol=1 ,984 µl, t(9)=4.2, p<0.01 and 41,−3,12, vol=896 µl; t(9)=3.5, p<0.01)] and two in the left insula [−51,34,18, vol=704 µl t(9)=4.5; p<0.01 and −41,12,17, vol=512 µl t(9)=3.95, p<0.01] during the escitalopram condition. However, extracting the previous four clusters and masking these functionally defined regions onto the other two contrasts (i.e., fearful-oval and happy-oval) showed no significant activation for the fearful or happy emotions (data not shown). The fearful-oval comparison reflected a cluster in the left amygdala (−25,−4,−15; vol= 320 µl) suggesting attenuation of this area after escitalopram treatment [t(9)=3.2, p=0.01]. When this latter cluster was used to extract activation in the happy and angry contrast, a marginal effect of escitalopram was detected for anger [t(9)=2.1, p=0.07)] but not for happy [t(9)=1.3, p> 0.1], suggesting an effect of emotional valence (see Fig. 5 ). Interestingly, the strongest task activation was observed for the fearful-oval contrast (data not shown).
Discussion
The aim of this study was to investigate whether subchronic (21 days of) escitalopram treatment would attenuate emotion-processing-related activation in limbic and paralimbic structures. Escitalopram did not affect behavior on this task nor did it change levels of anxiety in these healthy volunteers. The escitalopram treatment phase (compared to the placebo treatment phase) was not associated with an altered BOLD response to the task when including all subjects in the analysis. However, when urinary concentrations of escitalopram (which had been collected primarily as an indicator of SSRI adherence) were considered, strong concentration-dependent relationships between amygdala and insular activity were observed. An additional set of analyses including only the 10 of 13 subjects with concentrations of escitalopram in urine that were well above the assay detection threshold (which we interpreted as indicative of good compliance with the escitalopram administration) revealed a significant attenuation for fearful faces and a marginal attenuation for angry but not for happy faces. Taken together, these observations suggest that there was an attenuation of BOLD activity in the bilateral insula and amygdala (but not in the fusiform gyrus) directly related to bioavailability of escitalopram and a direct attenuation for negative faces in those who most likely complied with chronic administration of escitalopram. Because we had not measured plasma concentrations of escitalopram (and metabolites) at various phases of the study, there is some uncertainty as to whether blood (and, by inference, brain) concentrations of escitalopram do, indeed, correlate with the observed BOLD fMRI responses. Thus, future work will be required, using pharmacodynamic modeling, to confirm these suspected effects.
In line with a recent fMRI study by Harmer et al. (2006) , our results suggested that subchronic SSRI administration attenuates amygdala activation (when compared against placebo) to negatively but not positively valenced emotional faces. Similarities with the current study include same population type (i.e., healthy volunteers) and subchronic SSRI treatment. Nevertheless, some important differences should be noted. Regarding the behavioral paradigm, the current participants were presented with unmasked (vs masked in the Harmer et al. 2006 study) presentations of facial expressions, which also differed in the emotion depicted (anger, fear, and happiness as opposed to threat and happiness). Additionally, the fMRI task used by the Harmer et al. group did not include a sensorimotor condition, and subjects were asked to judge the gender of the face vs matching its affect. Duration of treatment is three times longer in the current study (21 vs 7 day administration). Finally, and perhaps most importantly, the current study is a double-blind placebo-control crossover vs a double-blind between groups design in which treatment compliance was not reported.
Our results are consistent with a presumed role for amygdala activation in anxiety and depression. The amygdala is involved during fear conditioning (Charney 2003) , and it has been suggested that its malfunctioning is a stable feature of depression (Mayberg et al. 1999 ) and anxiety disorders Brain areas that significantly correlated with regions of interest related to urine concentration levels during escitalopram administration in 13 subjects (Stein et al. 2002) or post-traumatic stress disorder (Rauch et al. 2000) . Thus, the attenuation of amygdala activity after escitalopram treatment provides evidence for the direct action of SSRIs in emotion processing structures regardless of symptom attenuation (Fu et al. 2004; Harmer et al. 2006) and bridges a direct translation of previous findings of serotonin-induced cell firing inhibition in animal amygdala (Harmer et al. 2006; Stutzmann and Ledoux 1999) .
An unexpected opposite effect (greater activation with escitalopram) was revealed in the insula. However, several aspects may account for this result. First, this effect was restricted to the emotion of anger (as opposed to the amygdala attenuation that was valence dependent). Second, the task effect for angry was not as robust as for the fear contrast, suggesting that it may be the result of lack of power due to the reduced number of subjects (n=10). Furthermore, results from the regression analysis suggested that escitalopram attenuates activation in the insular cortex on a urine concentration-dependent basis. A recent review paper published by our group postulates that individuals prone to anxiety disorders present an altered interoceptive predictive signal . Interoception involves the self-perception of bodily signals that are important for internal body integrity and the connections that are crucial for allocating attention, contextual evaluation, and action planning. The insula is the structure tasked with evaluating the impact that certain stimuli may have in the body state. Insula activation correlates with anxiety indices during a risk-taking task (Paulus et al. 2003) and is heightened in subjects with specific phobia when viewing fearful faces ) and in subjects with high trait anxiety Stein et al. 2006 Stein et al. , 2007 . Because activation in the insular cortex has been associated with the processing of affective modulation, cognitive processing during learning, and interoception of aversive stimuli, the insula emerges as a structure that links emotion, cognition, and behavior. In summary, the link between altered insular function and several anxiety disorders (Hoehn-Saric et al. 2004; Lorberbaum et al. 2004; Malizia et al. 1998; Mataix-Cols et al. 1999; Rauch et al. 1997; Wright et al. 2003 ) suggests a common denominator that could be used as a biomarker for their treatment.
To our knowledge, this is the first study to show that an antidepressant drug can reduce not only amygdala but possibly insular cortex activation. Similarly to other studies that have detected ventral anterior cingulate cortex attenuation after SSRI treatment in normal volunteers (Harmer et al. 2006) and those who successfully recovered from depression (Mayberg et al. 2000) , our findings support a role for this area in the modulation of affective material (Whalen et al. 1998 ). Our results also provide another piece of evidence for the potential utility of pharmaco-fMRI (Arce et al. 2006; Harmer et al. 2006; Paulus et al. 2005) to delineate the neurocircuitry involved the treatment of anxiety and affective disorders.
SSRIs were developed to regulate serotonin levels within the central serotonin 5-HT2 receptor to treat affective disorders (Mendlewicz 1999) . Rodent studies have suggested that escitalopram may be effective in reducing aggressive behavior , panic-like anxiety (Hogg et al. 2006) , and reverse conditioned fearrelated behaviors . The current findings of reduced limbic and paralimbic activity after escitalopram treatment contribute to our understanding of how SSRIs can be effective therapeutic agents in the treatment of a broad array of disorders such as anxiety and depression; that is, the selective attenuation of emotion processing structures, as opposed to overall brain activation changes (i.e., lack of attenuation in motor or fusiform gyrus), provides evidence for the specificity of SSRIs in targeting relevant processes in the pathophysiology of anxiety and mood disorders. Studies with depressive and anxious individuals should be conducted to explore whether the current findings can be translated from healthy volunteers to clinical populations.
This study has a number of limitations. Foremost among these is the lack of escitalopram blood levels. Thus, while we found a robust relationship between escitalopram urine Fig. 5 Amygdala attenuation due to sub-chronic escitalopram administration in ten subjects. Note: Brain regions depicted in the figure resulted from between-conditions (Placebo vs Escitalopram) Fearful-Oval Contrast in ten subjects. Areas were masked onto Happy-Oval and Angry-Oval contrasts to obtain the above percent signal change levels and activation in emotion-processing brain areas, we cannot be certain that higher urine levels can be considered to reflect higher blood (and brain) levels. The relationship between urine and plasma levels can be supported by a pharmacokinetic report that suggested consistency between both t 1/2 of urine and plasma (Sogaard et al. 2005) . We have also used urine levels to make inferences about compliance with escitalopram administration. This resulted in us excluding subjects with non-detectable or very low urine escitalopram levels, under the assumption that such subjects were non-compliant with the protocol. The limited sensitivity of the urine analysis test (5 to 2,000 Ng/ml) may have caused a possible range restriction effect given that 5 out of 13 individuals presented scores within the upper limit of the detection range. However, if anything, this would have reduced the power to detect correlations. Nevertheless, we have performed non-parametric tests to minimize the influence of this effect. Future pharmaco-imaging studies may incorporate urine and blood assays with greater assiduity to monitor compliance and determine the relationship between plasma levels and brain effects. Another consideration for future studies is that highly arousing and graphic images may be able to more effectively probe the therapeutic effects of pharmacological agents by assuring greater pretreatment levels of limbic and paralimbic hyperactivity, which can be reduced after treatment.
In summary, the current investigation provides additional neuroimaging evidence of a change in brain regions critical for the mediation of anxiety and depression induced by a well-established pharmacological agent, an SSRI. This study offers further support for the use of BOLD-fMRI in combination with pharmacological probes to assess neurophysiological models proposed for anxiety and depression and highlights the a role for fMRI in the evaluation of novel pharmacological treatments.
